Clinical Trial Update: Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab as second-line treatment for metastatic biliary tract cancer with integrated genomic analysis to identify predictive subt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Biliary Tract Cancer | Phase 2 | Status: COMPLETED